Issue 32

PSYCH Investor Summit: Research & Development

Four weeks until the upcoming PSYCH Investor Summit: Research & Development remain, and we’re pleased to announce the latest speakers in the programming:

Dr. Ben Sessa 
Chief Medical Officer
Awakn Life Sciences

Contextualised by the current research by the Awakn Life Sciences team, Dr. Sessa will highlight the condition of addiction and the potential of psychedelics as a treatment option.

Dr. Jennifer Mitchell
Professor of Neurology & Psychiatry
University of California San Francisco

Lead author of MAPS’ recent peer-reviewed paper which outlines results of its Phase 3 clinical trial, Dr. Mitchell will outline the condition of PTSD and how MDMA may help treat it.

Floris Wolswijkr 
Founder
Blossom Analytics 

Founder of the world’s leading repository for clinical research data, operator listings, intelligence and insight on psychedelic medicines, Floris will share a summary of ongoing clinical research by operators around the world.

Secure your seat today and join us on 7 July for these can’t-miss speakers.

Register Now

J.R. RAHN STEPS DOWN FROM MINDMED CEO POSITION

The company announced on Wednesday that Rahn, co-founder and CEO, would step down from the role, effective immediately. MindMed’s chief development officer Robert Barrow takes up the position of interim CEO.

Read More

AWAKN LIFE SCIENCES COMPLETES PRIVATE PLACEMENT

The previously announced brokered private placement has closed for gross proceeds of CAD$8.3 million. The offering was co-led by Cannacord Genuity Corp. and Eight Capital.

Read More

BUSINESS AND INVESTMENT

Everything investors need to know about the US’s first psychedelic stocks ETF.

Field Trip Health CEO talks about psychedelics company’s listing on Toronto Stock Exchange.

Study investigates psychedelics for COVID frontline workers.

CB Therapeutics’ latest psilocybin application highlights patent challenges facing psychedelics industry.

Groundbreaking COMPASS Pathways study finds psilocybin doesn’t negatively affect cognitive function.

Mydecine advances psilocybin research with discovery of new mushroom compounds with medical potential.

Red Light Holland acquires Silicon Valley applied science company.

Silo Pharma partners with university to study psilocybin anti-inflammatory agent.

The Psyence Group incorporates wholly owned subsidiary to formalise entry into Jamaica.

Filament Health partners with psychedelic research programme to progress drug development efforts.

MINDCURE completes first stage of manufacturing ibogaine for psychedelic clinical research.

PharmaTher seeks approval to explore ketamine as treatment for amyotrophic lateral sclerosis.

GH Research files for US$100 million to explore DMT depression treatment.

NUE Life Health raises US$3.3 million for psychedelics mental wellness platform.

Vireo Health diversifies into psychedelics and changes name to Goodness Growth Holdings.

Mindset selects lead clinical candidates for next-generation psychedelic medicine.

Ketamine One signs definitive agreement to acquire Integrated Rehab and Performance.

BetterLife Pharma appoints psychedelics medicine expert to Board of Directors.

First female-run psychedelics company looks to combat women’s health issues with psychedelics.

XPhyto completes initial batch production of mescaline for psychedelic therapies.

Ketamine One launches immersive virtual reality R&D programme at MindScape Clinic.

PSYCH Investor Summit: Research & Development

In today’s fast-moving psychedelics industry, brand awareness and thought leadership in front of a qualified audience are crucial for growing operators. Would your organisation benefit from connecting with a network of investors ready to deploy capital? Partnership opportunities for the upcoming PSYCH Investor Summit: Research & Development are still available. Enquire with our team to learn more.

Apply to Partner

RESEARCH AND SCIENCE

Studies show magic mushrooms treat depression, but stigma will be the real challenge.

The therapeutic potential of muscimol – from treating stress to improving sleep.

Explaining new ketamine infusion therapy for depression.

Commodification of psychedelics puts hallucinogenic toad in peril.

It’s time for world’s largest medical research funder to invest in medicinal psychedelics.

How valuable is the role of the mystical experience in psychedelic therapy?

Experts discuss continued growth of evidence of psychedelics’ medical benefits.

REGULATION AND LEGISLATION

Public supports leading scientists’ calls to change UK psychedelic drug research regulations.

New York lawmaker introduces bill to create state-funded psychedelics research institute.

Mushrooms on slate of psychedelics that could be legalised in New York.

Seattle City Council seeking decriminalisation of psychedelic drugs.

Connecticut governor OKs legislation that allows state-funded psilocybin study.

Psilocybin treatment can bring terminal patients peace, but Ottawa blocking access.

Andrew Yang proposes psychedelic therapies for veterans in New York mayoral race.

Partner with us